Author

J. Vykoukal

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 2 Organism:human· 2 Assay:metabolomics· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1

Frequent Co-Authors

E. Irajizad· 3 shared J. B. Dennison· 3 shared J. F. Fahrmann· 3 shared Y. Chen· 3 shared F. C. Hsiao· 2 shared H. Katayama· 2 shared M. J. Hong· 2 shared R. Wu· 2 shared

Activity by Year

2023-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

E. Irajizad

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Vesicle-mediated mitochondrial clearance underlies an actionable metabolic vulnerability in triple-negative breast cancer

J. Vykoukal, Y. Chen, M. J. Hong, M. Zuo, H. Krishna, H. Katayama, E. Irajizad, R. Wu, R. Leon-Letelier, J. B. Dennison, A. Gutierrez, A. Paulucci-Holthauzen, T. C. Thompson, L. Rusling, Y. Cai, , J. F. Fahrmann

The paper identifies a metabolic vulnerability in triple-negative breast cancer through sphingolipid metabolism, showing that targeting this pathway with eliglustat reduces tumor growth and improves survival.

bioRxiv · Apr 4, 2024 · PreprintCancer Biology

Integrated spatial transcriptomics and lipidomics of precursor lesions of pancreatic cancer identifies enrichment of long chain sulfatide biosynthesis as an early metabolic alteration

M. Sans, Y. Chen, F. I. Thege, R. Dou, J. Min, M. Yip-Schneider, J. Zhang, R. Wu, E. Irajizad, Y. Makino, K. I. Rajapakshe, M. W. Hurd, R. A. Leon, J. Vykoukal, J. B. Dennison, , J. F. Fahrmann

bioRxiv · Aug 14, 2023 · PreprintCancer Biology

EGFR inhibition in lung adenocarcinoma upregulates cell surface expression of the placental antigen ALPP and enhances efficacy of ALPP-ADC therapy

y. chen, M. J. Hong, H. Xu, J. Vykoukal, S. Park, y. Cai, R. A. Leon-Letelier, E. Irajizad, F. C. Hsiao, J. B. Dennison, E. J. Ostrin, J. F. Fahrmann, H. Katayama, S. M. Hanash

The paper shows EGFR inhibition increases ALPP surface expression in lung adenocarcinoma, enhancing the effectiveness of ALPP-ADC therapy.

bioRxiv · Mar 27, 2023 · PreprintCancer Biology